We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
In another blow to Genentech’s blockbuster cancer drug Herceptin, a federal appeals court upheld the U.S. Patent Trial and Appeals Board’s invalidation of two patents it holds on the drug. Read More
The EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended AveXis’ spinal muscular atrophy gene therapy Zolgensma along with seven other medicines at its March meeting. Read More
Mylan said it will waive its exclusive U.S. distribution rights for its copycat of AbbVie’s HIV antiviral Kaletra (lopinavir/ritonavir) to allow other suppliers to manufacture the potential COVID-19 treatment. Read More
President Trump signed a stimulus measure Friday that would help prevent drug shortages and change how the FDA deals with over-the-counter drugs. Read More
The FDA said it won’t object to outsourcing facilities using hydroxychloroquine sulfate or chloroquine phosphate for compounding during the COVID-19 pandemic. Read More
China’s National Medical Products Administration (NMPA) has banned the importation, sale and use of Bristol-Myers Squibb’s cancer blockbuster Abraxane (nanoparticle albumin-bound paclitaxel) following an inspection in the U.S. Read More
The Canadian government has passed a law that temporarily speeds up its process for overriding drug patents, to ensure accessibility to medically necessary products during the coronavirus pandemic. Read More